The increasing role of PDE5Is in men with diabetes and cardiovascular disease

Abstract

Diabetes is strongly associated with erectile dysfunction, which is itself a risk factor for cardiovascular events and mortality. Evidence shows that phosphodiesterase type 5 inhibitor (PDE5I) use in men with type 2 diabetes mellitus is associated with a significant reduction in all‐cause mortality and morbidity. Despite the evidence, PDE5Is appear to be underused in this male cohort.